文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤放疗物理与技术

复发性前列腺癌接受68Ga-PSMA配体PET/CT引导放射治疗后的进展模式

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-09-07

本研究纳入108例原发治疗后复发性寡转移性前列腺癌患者,接受68Ga-PSMA配体PET/CT引导的放射治疗。中位随访18个月后,43.5%(47/108)出现生化进展,估计生化无进展生存期为16个月;再次PET/CT可定位91.7%(33/36)的复发病灶,累积野内复发率12.1%(4/33),野外复发率87.9%(29/33)。

要点

  • 68Ga-PSMA配体PET/CT引导RT后97.2%(105/108)患者PSA下降,为生化应答者。
  • 中位随访18个月,43.5%(47/108)生化进展,估计生化无进展生存期16个月。
  • 进展模式以野外复发为主(87.9%,29/33),野内复发为12.1%(4/33)。

核心结论

  • PSMA配体PET/CT引导RT对肿瘤负荷有限的复发性前列腺癌可实现个体化治疗,提供有效局部控制,并带来相当延长的生化无进展生存期。
  • 基于PSMA配体PET/CT的进展模式提示,重复PET/CT引导RT可能作为寡转移性疾病RT后复发且选择合适患者的一种治疗选择。

研究设计与样本

  • 纳入108例原发治疗后复发性寡转移性前列腺癌、PSA升高并接受68Ga-PSMA配体PET/CT引导RT的患者。
  • 确定PSMA配体PET/CT引导RT后的生化无进展生存期和远处无病生存期。
  • 对生化进展患者再次行68Ga-PSMA配体PET/CT确定进展模式,并与RT临床靶体积比较,记录野内和野外复发频率。

主要发现

  • 97.2%(105/108)患者RT后PSA下降,归类为生化应答者。
  • 中位随访18个月,43.5%(47/108)出现生化进展,估计生化无进展生存期为16个月。
  • 再次68Ga-PSMA配体PET/CT在91.7%(33/36)患者中定位复发病灶。
  • 进展模式分析显示累积野内复发率12.1%(4/33),累积野外复发率87.9%(29/33)。
  • 中位无病生存期为11个月;观察到转移模式向骨受累和远处淋巴结转移转变;45.5%(15/33)患者接受进一步RT以延迟启动或升级全身治疗。

关键数值与推荐

  • 生化应答定义为RT后PSA下降,97.2%(105/108)患者符合。
  • 累积野内复发率12.1%(4/33),累积野外复发率87.9%(29/33)。
  • 中位生化无进展生存期16个月,中位无病生存期11个月。

临床怎么用

  • 作者认为,PSMA配体PET/CT引导RT可为肿瘤负荷有限的复发性前列腺癌提供个体化治疗并实现有效局部控制。
  • 作者认为,基于PSMA配体PET/CT的进展模式,重复PET/CT引导RT可能作为寡转移性疾病RT后复发且选择合适患者的一种治疗选择。
  • 45.5%(15/33)进展患者接受进一步RT以延迟启动或升级全身治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the patterns of progression after 68Ga prostate-specific membrane antigen (PSMA)-ligand positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy (RT) for recurrent oligometastatic prostate cancer (PCa). METHODS AND MATERIALS: One hundred and eight patients with increased prostate-specific antigen levels, who received 68Ga-PSMA-ligand PET/CT-guided RT for recurrent oligometastatic disease after primary therapy for PCa were included. The biochemical progression-free survival and distant disease-free survival after PSMA-ligand PET/CT-guided RT were determined. The patterns of progression were determined using renewed 68Ga-PSMA-ligand PET/CT in patients with biochemical progression and compared with the clinical target volume of the 68Ga-PSMA-ligand PET/CT-guided RT. The frequency of infield and outfield relapses was recorded. RESULTS: A total of 97.2% (105 of 108) of patients showed a decrease in prostate-specific antigen levels after RT and were classified as biochemical responders. After the median follow-up of 18 months, 43.5% (47 of 108) of the patients experienced biochemical progression, resulting in an estimated biochemical progression-free survival of 16 months. Renewed 68Ga-PSMA-ligand PET/CT allowed localization of recurrent disease in 91.7% (33 of 36) of patients. Analysis of the patterns of progression resulted in a cumulative infield relapse rate of 12.1% (4 of 33) and a cumulative outfield relapse rate of 87.9% (29 of 33). The resultant median disease-free survival was 11 months. In terms of the pattern of progression, we observed a shift in the pattern of metastases toward skeletal involvement and distant lymph node metastases. Of these patients, 45.5% (15 of 33) were treated with further RT to delay initiation or escalation of systemic therapies. CONCLUSION: PSMA-ligand PET/CT-guided RT for relapsed PCa with limited tumor burden allowed individualization of treatment approaches, provided effective local control, and resulted in considerably prolonged biochemical progression-free survival. As indicated by the PSMA-ligand PET/CT-based patterns of progression, repeated PET/CT-guided RT may represent a treatment option in well-selected patients with relapse after RT for oligometastatic disease.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Soldatov A, von Klot CAJ, Walacides D, et al. Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30201438. doi:10.1016/j.ijrobp.2018.08.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。